FibroGen, Inc. (FGEN)

1.1500 -0.0200 (-1.71%) As of 10:35AM EDT. Market open.

FibroGen, Inc.

409 Illinois Street
San Francisco, CA 94158
United States
415 978 1200
https://www.fibrogen.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 486

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Thane Wettig	CEO & Director	807.35k	N/A	1965
Mr. Juan Graham	Senior VP & CFO	991.76k	N/A	1977
Ms. Christine L. Chung	Senior Vice President of China Operations	1.27M	N/A	1968
Dr. Barry A. Berkowitz Ph.D.	Founder	N/A	N/A	N/A
Dr. John J. Hunter Ph.D.	Chief Scientific Officer	N/A	N/A	1963
David DeLucia	Vice President of Corporate FP&A and Investor Relations	N/A	N/A	N/A
Mr. Michael D. Lowenstein J.D., Ph.D.	Chief Legal Officer	N/A	N/A	N/A
Ms. Tricia Stewart	Chief People Officer	N/A	N/A	N/A
Mr. Kirk A. Christoffersen MBA	Chief Business Officer	N/A	N/A	1969
Dr. Rahul Rajan Kaushik Ph.D.	Senior Vice President of Pharmaceutical Development, Technical Operations & Manufacturing	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Corporate governance

FibroGen, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 9; Board: 2; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.